Clinical trials · New York, NY
Acute Lymphoblastic Leukemia clinical trials in New York
We’re tracking 44 recruiting acute lymphoblastic leukemia studies with a site in or near New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
New York, New YorkAges 18 years+ - NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
New York, New YorkAges 1 year–46 years - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
New York, New YorkAges 18 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
New York, New YorkAges Up to 22 years - NCT06918431RecruitingPhase 2
Erwinia asparaginase with chemo for new ALL or LBL
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
New York, New YorkAges 18–54 - NCT07400029RecruitingPhase 2
Obecabtagene autoleucel for B-cell ALL in remission
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
New York, New YorkAges 40 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
New York, New YorkAges Up to 12 months - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
New York, New YorkAges 12 years+ - NCT05848687RecruitingPhase 1/Phase 2
Newborns with CD19 leukemia may try a combined infant therapy
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
New York, New YorkAges Up to 1 year - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
New York, New YorkAges Any age - NCT03666000RecruitingPhase 1
Azer-cel for B-cell lymphoma and leukemia that has returned
This trial tests an investigational cell therapy called Azer-cel for people with certain types of blood cancer (non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia) that has come back or not responded to previous treatments. The therapy uses your own immune cells that have been modified to find and attack cancer cells.
New York, New YorkAges 18 years+ - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
New York, New YorkAges 4 weeks+ - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
The Bronx, New YorkAges 18 years+ - NCT06308588RecruitingPhase 1/Phase 2
Blinatumomab and asciminib for Ph+ ALL
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
The Bronx, New YorkAges 18 years+ - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
The Bronx, New YorkAges 6–39 - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
Hackensack, New JerseyAges 1–25 - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Lake Success, New YorkAges 60 years+ - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Valhalla, New YorkAges Up to 21 years - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Valhalla, New YorkAges 13–90 - NCT04929899Recruiting
Test of a learning tool during leukemia maintenance
This study checks whether a tablet-based tool (called PeNAT) can be used by children during the usual maintenance treatment phase for ALL (a type of leukemia). It may help families and clinicians better support care at home or during follow-up by testing how well the tool works in real patients.
New Brunswick, New JerseyAges 4–18
Hear when a new Acute Lymphoblastic Leukemia trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Acute Lymphoblastic Leukemia trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting acute lymphoblastic leukemia studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Hackensack University Medical Center · 7 studies
- Montefiore Medical Center · 5 studies
- New York Medical College · 4 studies
- NYU Langone Health · 4 studies
- Rutgers Cancer Institute of New Jersey · 4 studies
- Memorial Sloan Kettering Basking Ridge · 3 studies
- Memorial Sloan Kettering Bergen · 3 studies
What taking part in a acute lymphoblastic leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting acute lymphoblastic leukemia studies in New York.
Common questions
- Are there acute lymphoblastic leukemia clinical trials near New York?
- Yes. We're currently tracking 44 recruiting acute lymphoblastic leukemia studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute lymphoblastic leukemia study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute lymphoblastic leukemia studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.